istopmm: a new, large & unbiased mgus patient population
Published 2 years ago • 208 plays • Length 0:42Download video MP4
Download video MP3
Similar videos
-
2:47
istopmm analysis results: autoimmune diseases are not associated with mgus
-
3:26
the risk of thrombotic events in patients with mgus: an analysis from the istopmm trial
-
1:43
an insight into the prevalence of various subtypes of mgus in the istopmm study
-
5:11
istopmm: the psychological effects of mgus screening and changes to clinical presentation of myeloma
-
2:16
what does the future of mgus look like?
-
5:26
updates from the istopmm study
-
2:14
a new classification for identifying high-risk myeloma based on cytogenetic abnormalities
-
21:38
drawing the line: the rationale behind blood tube collection order
-
2:16
living with multiple myeloma
-
14:43
current research into post-allosct maintenance therapy in aml
-
2:04
key takeaways from the istopmm trial: screening for mgus
-
9:25
mgus diagnosis: a step-by-step approach
-
2:12
allosct for aml with mds-related features as per the icc and who 2022 classifications
-
2:10
results of istopmm: prevalence of smoldering myeloma in the general population
-
1:05
istopmm: benefits and harms of screening for myeloma precursor disease
-
0:44
istopmm study – the impact of nationwide screening
-
3:08
welcome to the video journal of hematology & hematological oncology 🎥🩸
-
2:11
the genomic landscape of igm mgus & stable vs progressive asymptomatic wm
-
2:12
results from phase i study of alnuctamab administered intravenously & subcutaneously in r/r myeloma
-
1:47
shared treatment decision-making
-
2:09
heart transplantation in attr amyloidosis